Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma

X
Trial Profile

A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary)
  • Indications Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms NEO-CESQ
  • Most Recent Events

    • 06 Jun 2023 Results (n=23; From May 2021 to October 2022) assessing the efficacy and safety of neoadjuvant plus adjuvant cemiplimab in patients with surgically resectable, high-risk stage III/IV cutaneous squamous cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Feb 2023 Status changed from recruiting to active, no longer recruiting.
    • 27 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Oct 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top